UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. ブルーリ潰瘍（マイコバクテリウム・ウルセランス感染） buruli ulcer mycobacterium ulcerans infection
2. 小児の皮膚や軟部組織に発症する非結核性抗酸菌症 nontuberculous mycobacterial skin and soft tissue infections in children
3. 成人における非結核性抗酸菌による骨髄炎の治療 treatment of osteomyelitis due to nontuberculous mycobacteria in adults
4. ジフテリアの疫学および病態生理 epidemiology and pathophysiology of diphtheria
5. 非結核性抗酸菌による骨髄炎の疫学、臨床症状、および診断 epidemiology clinical manifestations and diagnosis of osteomyelitis due to nontuberculous mycobacteria

English Journal

The discovery, function and development of the variable number tandem repeats in different Mycobacterium species.

Sun Z1, Li W2, Xu S2, Huang H2.
Critical reviews in microbiology.Crit Rev Microbiol.2016 Sep;42(5):738-58. doi: 10.3109/1040841X.2015.1022506. Epub 2015 Jun 19.
The method of genotyping by variable number tandem repeats (VNTRs) facilitates the epidemiological studies of different Mycobacterium species worldwide. Until now, the VNTR method is not fully understood, for example, its discovery, function and classification. The inconsistent nomenclature and term
PMID 26089025

Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.

Klis S1, Kingma RA1, Tuah W2, van der Werf TS1,3, Stienstra Y1.
Tropical medicine & international health : TM & IH.Trop Med Int Health.2016 Jul 26. doi: 10.1111/tmi.12745. [Epub ahead of print]
OBJECTIVES: Buruli ulcer (BU) is a tropical skin disease caused by infection with Mycobacterium ulcerans, which is currently treated with 8 weeks of streptomycin and rifampicin. The evidence to treat BU for a duration of 8 weeks is limited; a recent retrospective study from Australia suggested that
PMID 27456068

Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases.

Conti F1, Lugo-Reyes SO2, Blancas Galicia L2, He J3, Aksu G4, Borges de Oliveira E Jr5, Deswarte C6, Hubeau M6, Karaca N4, de Suremain M6, Guérin A6, Baba LA7, Prando C8, Guerrero GG6, Emiroglu M9, Öz FN10, Yamazaki Nakashimada MA11, Gonzalez Serrano E11, Espinosa S11, Barlan I12, Pérez N13, Regairaz L13, Guidos Morales HE14, Bezrodnik L15, Di Giovanni D15, Dbaibo G16, Ailal F17, Galicchio M18, Oleastro M19, Chemli J20, Danielian S19, Perez L19, Ortega MC21, Soto Lavin S22, Hertecant J23, Anal O24, Kechout N25, Al-Idrissi E26, ElGhazali G26, Bondarenko A27, Chernyshova L27, Ciznar P28, Herbigneaux RM29, Diabate A30, Ndaga S30, Konte B30, Czarna A30, Migaud M6, Pedraza-Sánchez S31, Zaidi MB32, Vogt G6, Blanche S33, Benmustapha I34, Mansouri D35, Abel L36, Boisson-Dupuis S36, Mahlaoui N37, Bousfiha AA17, Picard C38, Barbouche R34, Al-Muhsen S39, Espinosa-Rosales FJ11, Kütükçüler N4, Condino-Neto A40, Casanova JL41, Bustamante J42.
The Journal of allergy and clinical immunology.J Allergy Clin Immunol.2016 Jul;138(1):241-248.e3. doi: 10.1016/j.jaci.2015.11.041. Epub 2016 Feb 28.
BACKGROUND: Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by inborn errors of the phagocyte nicotinamide adenine dinucleotide phosphate oxidase complex. From the first year of life onward, most affected patients display multiple, severe, and recurrent infections cause
PMID 26936803